# Madison Vaccines Incorporated

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/madison-vaccines

- Industry: Pharmaceuticals
- Headquarters: Madison, US
- Website: www.madisonvaccinesinc.com
- Total disclosed funding: $8.5M
- Latest round: Series A (Mar 10, 2015)
- Investors on record: 5

## About

Madison Vaccines Incorporated is dedicated to developing innovative immunotherapies, particularly in the field of oncology, focusing on DNA vaccines to enhance the body’s natural immune response against cancer.Madison Vaccines Incorporated is engaged in the development of DNA vaccine therapies, particularly targeting non-metastatic prostate cancer. Founded by Douglas McNeel, the company is headquartered in Madison, US. In March 2015, Madison Vaccines raised USD 2.000 mn in Series A funding from investors including Venture Management LLC, WARF Ventures, and Venture Investors, bringing the total amount raised to USD 2.000 mn with a current company valuation of USD 15.024 mn.Madison Vaccines Incorporated specializes in developing DNA vaccine therapies aimed at treating prostate cancer. Their core offerings include immunotherapy solutions designed to activate the immune system against cancer cells, focusing on enhancing patient outcomes through innovative approaches to cancer treatment. The company is positioned to serve both clinical and research communities interested in advanced cancer therapies.Madison Vaccines Incorporated's revenue model is based on investments and funding received for the development of their vaccine therapies. The recent funding raised through Series A will support their ongoing clinical trials and research initiatives, although specific pricing plans or direct revenue streams have not been detailed.Madison Vaccines Incorporated plans to utilize the USD 2.000 mn raised in Series A funding to advance its pipeline, particularly focusing on completing an expanded Phase 2 clinical trial for their DNA vaccine MVI-816, which targets non-metastatic prostate cancer patients with rapidly rising PSA levels. The company aims to bolster its development efforts and may explore further opportunities in oncology markets to enhance their therapeutic offerings.

## Funding rounds

- Series A, Mar 10, 2015, $2M — Venture Investors, Venture Management LLC, WARF Ventures
- Series A, Dec 23, 2014, $4.1M — Venture Investors
- Series A, Jan 21, 2014, $2.4M — Venture Investors, State of Wisconsin Investment Board, Wisconsin Investment Partners, Venture Management LLC, WARF Ventures

## Investors

- Venture Investors — Series A
- State of Wisconsin Investment Board — Series A
- Wisconsin Investment Partners (https://capitalatlas.ai/funds/wisconsin-investment-partners) — Series A
- Venture Management LLC — Series A
- WARF Ventures (https://capitalatlas.ai/funds/warf-ventures) — Series A